Oncogenic activation of the PI3K/AKT pathway either by activating mutations in PI3K, AKT genes or loss of function alterations in tumor suppressor phosphatase and tensin homolog (PTEN) are frequent events in prostate cancer [1]. The gene discussed is AKT1; the disease is prostate carcinoma.